Skip to main content
NIH funding notice PAR-23-195

Simultaneous and Synergistic Multi-Target Validation for Alzheimers Disease-Related Dementias (R61/R33 Clinical Trial not allowed)

Closed on September 15, 2023.

Posted
June 20, 2023
Close date
September 15, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,707,089 in first-year total cost, median $1,707,089.

Most frequent study sections

  1. Special Emphasis Panel[ZNS1 SRB-M (19)]1

Most frequent institutions

  1. NORTHWESTERN UNIVERSITY AT CHICAGO1
Competing awards under PAR-23-195 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2024Synergistic Enhancement of ER proteostasis, trafficking, and lysosomes as treatments for Dementia with Lewy bodies and Parkinson’s disease-dementia1R61NS138063-01MAZZULLI, JOSEPH RNORTHWESTERN UNIVERSITY AT CHICAGO, IL$1,707,089ZNS1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.